BRIEF published on 03/11/2026 at 18:35, 12 days 22 hours ago Inoviem Scientific Advances Drug Development with Patient-Centric Approach Personalized Medicine Pharmaceutical Innovation Inoviem Scientific Patient-centric Drug Development Preclinical Programs
PRESS RELEASE published on 03/11/2026 at 18:30, 12 days 23 hours ago ATON: UPDATE ON THE ACTIVITIES OF ITS SUBSIDIARY INOVIEM SCIENTIFIC Aton Group's subsidiary, Inoviem Scientific, transforms drug development by prioritizing patient samples & AI technology, accelerating preclinical programs with high-value translational data AI Technology Drug Development Inoviem Scientific Aton Group Patient Sample
BRIEF published on 03/11/2026 at 18:20, 12 days 23 hours ago Inoviem Scientific: Advances in Pharmaceutical Development Personalized Medicine Pharmaceutical Development Translational Pharmacology Inoviem Scientific Integrated Platform
BRIEF published on 02/18/2026 at 18:35, 1 month 5 days ago Hadrien Lanvin Appointed Deputy CEO of Aton Group Biotechnology Strategic Growth Deputy CEO Hadrien Lanvin Aton Group
BRIEF published on 02/18/2026 at 18:35, 1 month 5 days ago Hadrien Lanvin appointed Deputy Managing Director of the Aton Group Biotechnology Life Sciences Appointment Hadrien Lanvin Aton Group
PRESS RELEASE published on 02/18/2026 at 18:30, 1 month 5 days ago ATON APPOINTS HADRIEN LANVIN AS DEPUTY CEO Aton Group appoints Hadrien Lanvin as Deputy CEO to drive value and visibility, strengthening leadership and strategic positioning. Focus on maximizing asset portfolio valuation and accelerating development Valuation Leadership Deputy CEO Hadrien Lanvin Aton Group
BRIEF published on 10/31/2025 at 18:05, 4 months 23 days ago 2025 Half-Year Results: Aton Confirms its Recovery Financial Recovery 2025 Results PIMS Technology Inoviem Scientific B Cell Design
BRIEF published on 10/08/2025 at 18:05, 5 months 15 days ago Strategic partnership between Inoviem Scientific and abc biopply in preclinical oncology Strategic Partnership 3D Models Therapeutic Innovation Preclinical Oncology Translational Pharmacology
BRIEF published on 09/29/2025 at 08:05, 5 months 25 days ago ATON Presents its New Strategy at the European MidCap Event 2025 Investors Governance Financial Strategy Aton European MidCap
BRIEF published on 09/17/2025 at 18:05, 6 months 6 days ago PIMS Technology secures €500,000 in funding from Bpifrance Funding Marketing Precision Medicine Bpifrance PIMS Technology
Published on 03/24/2026 at 13:30, 4 hours ago GGL Resources Corp. Announces Closing of Earn-In Agreement with Nelson Resources Limited on Its Gold Point High-Grade Gold-Silver Project, Nevada
Published on 03/24/2026 at 12:35, 4 hours 55 minutes ago Silver X Acquires the High-Grade Pampas Gold-Silver Project, Expanding its Precious Metal Asset Base in Peru
Published on 03/24/2026 at 12:33, 4 hours 57 minutes ago Mako Mining Completes Acquisition of Mt. Hamilton in Nevada
Published on 03/24/2026 at 12:30, 5 hours ago Orogen Reports Record 2025 Financial Performance and Positions for Continued Growth in 2026
Published on 03/24/2026 at 16:50, 40 minutes ago LR Health & Beauty SE announces successful conclusion of the Written Procedure initiated on 6 March 2026 under the 2024/2028 Bonds and issuance of Super Senior Bonds
Published on 03/24/2026 at 16:14, 1 hour 16 minutes ago TenneT Germany receives preliminary inaugural S&P credit rating of BBB+ with stable outlook
Published on 03/24/2026 at 16:10, 1 hour 20 minutes ago EQS-Adhoc: IONOS Group SE decides to launch new share buyback program
Published on 03/24/2026 at 16:02, 1 hour 28 minutes ago Custodian Property Income REIT plc: Share Buyback
Published on 03/24/2026 at 17:16, 14 minutes ago Avaibility of the 2025 Universal Registration Document
Published on 03/24/2026 at 10:58, 6 hours 32 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of February 28, 2026
Published on 03/24/2026 at 07:45, 9 hours 45 minutes ago François Jackow’s appointment as a Board member will be submitted to the Annual General Meeting on May 7, 2026
Published on 03/24/2026 at 07:30, 10 hours ago Gimv secures new EUR 400 million revolving credit facility to support accelerated growth ambitions
Published on 03/23/2026 at 19:08, 22 hours 22 minutes ago Reporting on share buyback transactions carried out between March 16 and March 20, 2026
